Panic Disorders Global Market Report 2024

The panic disorders market size has grown strongly in recent years. It will grow from $10.19 billion in 2023 to $10.73 billion in 2024 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historical period can be attributed to the use of antidepressant medications, heightened awareness of mental health issues, rising stress levels, improved access to mental health services, and advancements in diagnostic criteria.

The panic disorders market size is expected to see strong growth in the next few years. It will grow to $13.07 billion in 2028 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to the emergence of pharmacological treatments, the expansion of telepsychiatry services, a focus on comorbidities, global mental health initiatives, the integration of pharmacogenomics in treatment, and public education programs. Major trends in the forecast period include digital mental health interventions, the use of telemedicine for panic disorder treatment, innovations in medications, advancements in neurobiological research, and the adoption of remote monitoring and wearable technology.

An upsurge in the population of psychiatric patients is poised to propel the expansion of the panic disorder market in the foreseeable future. Psychiatric patients, affected by mental health conditions that disrupt various aspects of their cognitive, emotional, and social functioning, are susceptible to panic disorder, characterized by sudden and intense episodes of anxiety. Treatment for individuals dealing with psychiatric conditions often involves a multifaceted approach combining therapy, medication, and lifestyle modifications to alleviate panic attack symptoms, enhance overall well-being, and foster effective coping mechanisms. For instance, the State of Mental Health in America 2022 report by Mental Health America noted an increase in psychiatric patients, reaching 49,564,000 individuals, constituting 19.86% of the total US population in 2022, compared to 47,132,000 individuals, comprising 19.00% of the total US population in 2021. Hence, the rise in psychiatric patient numbers is set to drive the growth of the panic disorder market.

The growing adoption of telehealth services is anticipated to propel the expansion of the panic disorders market in the coming years. Telehealth leverages electronic communication technologies such as video conferencing, phone calls, and secure messaging to deliver remote healthcare services and consultations. In the realm of panic disorders, telehealth enables psychotherapy and counseling services, offering platforms for therapists to conduct individual or group therapy sessions, as well as support groups, through secure video conferencing tools. As an illustration, a report by FAIR Health Inc. highlighted a 7.3% national increase in telehealth usage, from 5.5% of medical claim lines in December 2022 to 5.9% in January 2023. This growing reliance on telehealth platforms signifies a driving force behind the growth of the panic disorders market.

The high costs associated with panic disorder treatment and the limitations in insurance coverage can pose significant challenges, potentially restricting the market's growth during the forecast period. The expenses linked to managing panic disorder are often substantial due to the necessity for prolonged therapy, medications, and specialized care. Moreover, the constrained insurance coverage for mental health services frequently results in patients having to bear a significant portion of the treatment expenses. For instance, a report from Addiction Rehab Toronto in May 2021 indicated that anxiety treatment for a two-week session cost around $8,000, with a potential increase of $2,000 for treating PTSD and panic attacks. Cognitive-behavioral therapy (CBT) sessions could cost up to $100 per hour. Hence, the high treatment costs and limited insurance coverage serve as hindrances to the expansion of the panic disorder market.

Key companies engaged in the panic disorder market are concentrating on the development of advanced medications, notably extended-release capsules, to fortify their foothold in the market. Extended-release capsules are medications designed to gradually release the active ingredients over an extended period, typically 12 or 24 hours, suitable for managing conditions requiring prolonged medication. As an example, in May 2023, Granules India Ltd., an Indian pharmaceutical company, obtained abbreviated new drug application (ANDA) approval from the US Food & Drug Administration (USFDA) for Venlafaxine hydrochloride extended-release capsules. These capsules have demonstrated bioequivalence with the reference-listed drug product (RLD), Effexor XR Extended-Release Capsules, manufactured by Upjohn US 2 LLC. Venlafaxine HCl extended-release capsules are prescribed to manage various conditions such as generalized anxiety disorder (GAD), major depressive disorder (MDD), panic disorder (PD), and social anxiety disorder (SAD). They operate by increasing serotonin and norepinephrine levels in the brain, usually starting at a dosage of 75 mg per day and adjusted as required under a doctor's supervision.

In February 2023, Vistagen Therapeutics Inc., a clinical-stage biopharmaceutical company based in the United States, successfully acquired Pherin Pharmaceuticals Inc. for an undisclosed sum. This strategic acquisition positions Vistagen to advance and bring to market innovative treatments designed for individuals dealing with depression and anxiety disorders. The collaboration is anticipated to enhance the commercial prospects of each drug candidate, strengthening Vistagen's portfolio in addressing mental health challenges. Pherin Pharmaceuticals Inc., the acquired company, specializes in drug development focused on panic disorders.

Major companies operating in the panic disorders market report are F. Hoffmann-La Roche Ltd, Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH., Baxter Inc, Teva Pharmaceutical Industries Ltd, Mylan N.V., Pfizer Inc., Sun Pharmaceutical Industries Ltd, Bausch Health Companies Inc., H. Lundbeck A/S, Shionogi & Co Ltd., Recordati S.p.A, Neurocrine Biosciences Inc, Neuraxpharm, Actavis Plc., Noven Pharmaceuticals Inc., Sumitomo Pharma Co. Ltd, VistaGen Therapeutics, Valeant Pharmaceuticals International Inc., LIFECARE NEURO PRODUCTS LTD.

North America was the largest region in the panic disorders market in 2023. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the panic disorders market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa The countries covered in the panic disorders market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The panic disorder market consists of revenue earned by entities by providing services such as physical tests, cognitive behavioral therapy (CBT), and psychological evaluation. The market value includes the value of related goods sold by the service provider or included within the service offering. The panic disorder market includes sales of tablets and injectables. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The main subtypes of panic disorders include agoraphobia, social anxiety disorder (SAD), obsessive-compulsive disorder (OCS), bipolar disorder, post-traumatic stress disorder (PTSD), and major depressive disorder. Agoraphobia involves the intentional avoidance of places or situations that may trigger panic symptoms, leading to feelings of confinement, helplessness, or social discomfort. Various treatment options include medication, beta-blockers, serotonin and norepinephrine reuptake inhibitors (SNRIs), benzodiazepines, anti-epilepsy medications, and others, which can be administered orally, through injections, and other methods. These treatments are available through hospital pharmacies, retail pharmacies, and online pharmacy stores.

The panic disorders market research report is one of a series of new reports that provides panic disorders market statistics, including panic disorders industry global market size, regional shares, competitors with a panic disorders market share, detailed panic disorders market segments, market trends and opportunities, and any further data you may need to thrive in the panic disorders industry. This panic disorders market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.